Pathological mechanisms and therapeutic outlooks for arthrofibrosis

Abstract

Arthrofibrosis is a fibrotic joint disorder that begins with an inflammatory reaction to insults such as injury, surgery and infection. Excessive extracellular matrix and adhesions contract pouches, bursae and tendons, cause pain and prevent a normal range of joint motion, with devastating consequences for patient quality of life. Arthrofibrosis affects people of all ages, with published rates varying. The risk factors and best management strategies are largely unknown due to a poor understanding of the pathology and lack of diagnostic biomarkers. However, current research into the pathogenesis of fibrosis in organs now informs the understanding of arthrofibrosis. The process begins when stress signals stimulate immune cells. The resulting cascade of cytokines and mediators drives fibroblasts to differentiate into myofibroblasts, which secrete fibrillar collagens and transforming growth factor-β (TGF-β). Positive feedback networks then dysregulate processes that normally terminate healing processes. We propose two subtypes of arthrofibrosis occur: active arthrofibrosis and residual arthrofibrosis. In the latter the fibrogenic processes have resolved but the joint remains stiff. The best therapeutic approach for each subtype may differ significantly. Treatment typically involves surgery, however, a pharmacological approach to correct dysregulated cell signalling could be more effective. Recent research shows that myofibroblasts are capable of reversing differentiation, and understanding the mechanisms of pathogenesis and resolution will be essential for the development of cell-based treatments. Therapies with significant promise are currently available, with more in development, including those that inhibit TGF-β signalling and epigenetic modifications. This review focuses on pathogenesis of sterile arthrofibrosis and therapeutic treatments.

Arthrofibrosis: Drugs show promise for joint disease

“Stiff knee” or “frozen shoulder” syndrome, also known as arthrofibrosis, may come in two forms, active and residual,  which could benefit from different therapeutic interventions. A team led by Kayley Usher and Jiake Xu from the University of Western Australia in Crawley review the immune cells, signalling molecules and risk factors underpinning arthrofibrosis, a complication of surgery or trauma, in which scar tissue accumulates leading to painful restriction of motion in the shoulders, knees or other joints. The researchers propose the existence of two disease subtypes—one involving active scar formation, and one in which inflammatory processes have resolved—and they suggest each should be treated differently. Although surgery remains the most common intervention it may not be successful, and new research is highlighting the potential of pharmacological remedies, including those that block transforming growth factor-β signalling or target epigenetic modifications.